Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

Author's Avatar
Mar 02, 2023

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter and full-year ended December 31, 2022 and provided a corporate update.